Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors.

  • García-Carbonero, Rocio
  • Bazan-Peregrino, Miriam
  • Gil-Martín, Marta
  • Álvarez, Rafael
  • Macarulla, Teresa
  • Riesco-Martinez, Maria C
  • Verdaguer, Helena
  • Guillén-Ponce, Carmen
  • Farrera-Sal, Martí
  • Moreno, Rafael
  • Mato-Berciano, Ana
  • Maliandi, Maria Victoria
  • Torres-Manjon, Silvia
  • Costa, Marcel
  • Del Pozo, Natalia
  • Martínez de Villarreal, Jaime
  • Real Arribas, Francisco
  • Vidal, Noemí
  • Capella, Gabriel
  • Alemany, Ramon
  • Blasi, Emma
  • Blasco, Carmen
  • Cascalló, Manel
  • Salazar, Ramon
VCN-01 is an oncolytic adenovirus (Ad5 based) designed to replicate in cancer cells with dysfunctional RB1 pathway, express hyaluronidase to enhance virus intratumoral spread and facilitate chemotherapy and immune cells extravasation into the tumor. This phase I clinical trial was aimed to find the maximum tolerated dose/recommended phase II dose (RP2D) and dose-limiting toxicity (DLT) of the intravenous delivery of the replication-competent VCN-01 adenovirus in patients with advanced cancer.